Board of Medical Experts for VoyagerMed Highlights Breast Cancer Specialists
Industry: Healthcare
The VoyagerMed Board of Medical Experts has recruited some of the top specialists in breast cancer treatment in the country to care for medical tourism patients worldwide
New York (PRUnderground) August 31st, 2016
VoyagerMed announces that it has reached a significant milestone in its development. The company has added members to the Board of Medical Experts, an exclusive group of leading surgeons, physicians and doctors specializing in orthopedics, spine, fertility, cardiology, oncology, and plastic surgery. Learn more at: https://www.voyagermed.com/search/cancer/breast-cancer
Specialists that focus on breast cancer treatment include:
Adam M. Brufsky, MD, PhD, FACP, is professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicines Department of Medicine. Dr. Brufsky is the medical director of the Womens Cancer Center at Magee-Womens Hospital of UPMC and the University of Pittsburgh Cancer Institute (UPCI); associate director for clinical investigations at UPCI; and codirector of the Comprehensive Breast Cancer Center.
Dr. Brufsky is board-certified in internal medicine and medical oncology. He earned a medical and doctor of philosophy degrees from the University of Connecticut School of Medicine in Farmington, Conn.; completed a residency at Brigham and Womens Hospital, Harvard Medical School, and a fellowship at Dana-Farber Cancer Institute.
Dr. Brufsky is a member of professional organizations, such as American Medical Association, Massachusetts Medical Society, American College of Physicians, American Society of Clinical Oncology, American Association for Cancer Research, Allegheny County Medical Society, Pennsylvania Medical Society, and Pennsylvania Oncologic Society. An active researcher, Dr. Brufsky has numerous abstracts and research articles in leading journals, and is principal investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army – Breast Cancer Research Program.
Dr. Jonathan Cheng is a radiation oncologist in Baytown, Texas and is affiliated with Clear Lake Regional Medical Center. He received his medical degree from Keck School of Medicine of USC and has been in practice between 11-20 years. Dr. Cheng accepts several types of health insurance, listed below. He is one of 3 doctors at Clear Lake Regional Medical Center who specialize in Radiation Oncology. He also speaks multiple languages, including Chinese (Mandarin).
Dr. Calvin Han is a hematologist in Meadville, Pennsylvania and is affiliated with multiple hospitals in the area, including Forbes Regional Hospital and Meadville Medical Center. He received his medical degree from Saint Louis University School of Medicine and has been in practice between 11-20 years. He is one of 32 doctors at Forbes Regional Hospital and one of 2 at Meadville Medical Center who specialize in Hematology.
A pioneer in clinical cancer research, Dr. Holland’s contributions to the field include his role at the National Cancer Institute in 1953, where he began the first combination chemotherapy program in acute leukemia. His subsequent work with Tom Frei, J Freireich, Jean Bernard and members of Acute Leukemia Group B on acute lymphoblastic leukemia in children resulted in its transformation from incurability to an over 80 percent survival rate. He constructed the 7 and 3 regimen for acute myelocytic leukemia which is used worldwide and first identified cisplatin for testicular cancer and doxorubicin for osteosarcoma. Novel research on adjuvant and neo-adjuvant chemotherapy in these diseases and in breast and ovarian cancers influenced treatment protocols.
He and colleagues have recently described HMTV, the human mammary tumor virus, present in 40 percent of American women’s breast cancers that is 90 to 95 percent homologous to MMTV, the cause of breast cancer in mice. Dr. Holland also collaborated with Tom Frei to edit Cancer Medicine, an important reference that covers science and clinical applications for cancers. This specialty text, now in its eighth edition with additional co-editors, continues to influence oncologists worldwide.
Carol L. Kornmehl, M.D., F.A.C.R.O., is a board-certified radiation oncologist in Lakewood, New Jersey.
Dr. Kornmehl is a graduate of the State University of New York at Downstate Medical Center, where she also completed her radiation oncology residency. She was Medical Director of Radiation Oncology at Monmouth Medical Center, Long Branch, New Jersey from 1994-1997, Medical Director of New Jersey Radiation Therapy, Brick, New Jersey from 1998-2002 and Medical Director of St.Mary’s Passaic Hospital from 2006-2008.
Dr. Kornmehl is Clinical Assistant Professor of Radiation Oncology at Robert Wood Johnson/Rutgers College of Medicine and Drexel University College of Medicine. Previously, she was Assistant Professor of Clinical Radiology at the University of Medicine and Dentistry of New Jersey.
Dr. Kornmehl has received multiple honors, including listing in Who’s Who Among Rising Young Americans; How to Find the Best Doctors: New York Metro Area; National Registry of Who’s Who; and America’s Registry of Outstanding Professionals. She was elected a Fellow of the American College of Radiation Oncology for her exemplary service to the field.
Professional memberships include: American Society for Therapeutic Radiology and Oncology (where she served on several committees) 2004-2007, The Oncology Society of New Jersey (President 2004-2009), National Association of Medical Communicators, ProfNet, The American Society of Clinical Oncology, The American College of Radiology, The Oncology Society of New Jersey, The Eastern Cooperative Oncology Group, The Professional Advisory Board of The Wellness Community of Central New Jersey, The Radiologic Society of New Jersey, the Physician Advisory Board of iVillage.com Total Health and is a Healthology.com reviewer.
As an author, Dr. Kornmehl has been published in lay and scientific textbooks and journals.
Dr. Kornmehl is a member of the Editorial Boards of the 2006 Edition of the American Breast Cancer Guide, CURE Magazine and RT-Image Magazine.
She also serves as an expert about radiation therapy and cancer treatment to the media (see In The News and About the Doctor [Engagements]). She was the expert consultant for the chapter entitled Radiation Therapy in: Prostate Cancer: A Patient’s Guide to Treatment (Addicus Press, 2004); Straight Talk About Breast Cancer (Addicus Press, 2010); Lung Cancer; A Guide to Diagnosis & Treatment (Addicus Press, 2012) and Colon & Redd Cancer: From Diagnosis to Treatment (Addicus Press, 2012); In addition, Dr. Kornmehl is a member of the National Cancer Survivors Day Speakers Bureau.
Aye Moe Thu Ma, MD, is the director of Breast Surgery at Mount Sinai St. Luke’s. She is committed to providing novel, up to date approaches of benign and malignant breast diseases. Dr. Ma’s research in the areas of risk assessment, advanced cancers, and surgical complication reduction has been presented at numerous conferences and published in peer reviewed journals.
Dr. Alberto J. Montero is a Staff Physician in the Department of Solid Tumor Oncology. Dr. Montero’s clinical work focuses on breast cancer. Prior to joining the Cleveland Clinic, Dr. Montero was breast cancer site disease co-leader at the University of Miami Sylvester Comprehensive Cancer Center. Dr. Montero earned his medical degree from the University of Texas Medical Branch at Galveston, after which he completed a residency in internal medicine on the physician-scientist track at the University of Texas Houston Health Science Center.
He then completed his fellowship training in hematology/oncology at the University of Texas M.D. Anderson Cancer Center. Dr. Montero’s research interests include improvement of clinical outcomes in patients with breast cancer through the development of novel targeted therapies. He has been the principal investigator in over 30 clinical trials, and has co-authored over 50 peer reviewed publications. He has a particular interest in immune based therapies in breast cancer and other solid malignancies, and better understanding the various mechanisms by which tumors evade the immune system.
Dr. Montero also has a keen interest in process improvement in oncology to develop more effective and efficient treatment strategies in breast cancer that lead to better clinical outcomes and ultimately superior quality of care for patients. He is a Six Sigma Green Belt. Dr. Montero has also published several studies examining the cost-effectiveness of several targeted therapies currently utilized for the treatment of metastatic breast cancer.
Dr. Robinson Ortiz, M.D. attended college at Cornell University and obtained a Bachelor of Science in Neurobiology and Behavior. As an undergraduate student he spent his summer months volunteering at a community hospital which piqued his interest in medicine. He was named to the Dean’s List his final six semesters at Cornell.
Dr. Ortiz attended medical school at the University of Pennsylvania. While in medical school, he was the recipient of the Measy Foundation Scholarship for academic excellence (1998-2002). As a medical student he focused his clinical research on uncovering potential markers for the early detection of esophageal cancer.
In 2002 Robinson Ortiz, M.D. relocated to Chicago to continue his medical training at Northwestern Memorial Hospital. During his three year internal medicine residency he was awarded the Excellence in Teaching award. His research interests also led to a publication in the journal Bone Marrow Transplantation. Upon graduation he became board certified in Internal Medicine.
After completing his internal medicine residency, Robinson Ortiz, M.D. continued on to the University of Illinois at Chicago where he pursued fellowship training in both oncology and hematology. During his fellowship his research project regarding head and neck cancer was presented at the 2007 American Society of Clinical Oncology annual meeting. He was also recognized as the top performing fellow on the 2007 American Society of Oncology in-service exam. After completing his three year fellowship he became board certified in Medical Oncology.
Dr. Ortiz currently works in private practice with Northwest Oncology and Hematology S.C. He is credentialed at Advocate Good Shepherd Hospital, Alexian Brothers Medical Center, St. Alexius Medical Center and Northwest Community Hospital.
Dr. Paul Pagnini is a radiation oncologist in Glendale, California and is affiliated with multiple hospitals in the area, including Glendale Memorial Hospital and Health Center and Hollywood Presbyterian Medical Center. He received his medical degree from Tufts University School of Medicine and has been in practice for more than 20 years. Dr. Pagnini accepts several types of health insurance, listed below. He is one of 4 doctors at Glendale Memorial Hospital and Health Center and one of 4 at Hollywood Presbyterian Medical Center who specialize in Radiation Oncology.
Dr. Rajendran primarily practices at AMITA Health’s Alexian Brothers Medical Center and Illinois Gamma Knife Center. He is Board Certified in Radiation Oncology. He attended college at the University of Virginia and came to the Midwest for a combined MD/PhD program at the University of Illinois at Urbana-Champaign. Dr. Rajendran has a PhD in molecular mechanisms and cell biology of hormone dependent cancers such as breast cancer and prostate cancer. He did his residency training at the Hospital of the University of Pennsylvania in Philadelphia. He has also conducted research in the areas of prostate organ motion, proton radiation therapy, and radiation therapy for breast and thoracic tumors. He has written numerous papers and made presentations nationally and internationally.
Dr. Rajendran is trained in the use of 3-dimensional conformal radiation therapy, intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), gamma knife radiosurgery, high dose rate brachytherapy, and permanent interstitial brachytherapy. He has interest in treating a broad range of cancers including breast, lung, brain, genitourinary, head and neck, and gynecologic malignancies. He is also interested in cancer survivorship issues and empowering cancer patients and their care givers.
Dr. Rajendran enjoys spending his leisure time with his wife and two children camping, hiking, playing tennis, gourmet cooking, and wine tasting.
When asked why he chose radiation oncology, he states, “I began my love of cancer biology by studying cancer cells and I learned in medical training the art of caring for the entire patient. I strive to continually gain clinical knowledge to properly stage, plan, and treat my patients based on clinical evidence. I want to give my patients a clear understanding of how and why I am treating them. To really help a patient, it is critical to understand the science behind their treatment and the art of delivering care.”
Dr Schmidt is a board certified surgeon specializing in surgical oncology and particularly in care of patients with breast cancer. His background also includes training in Molecular Medicine and Genetics, and post-doctoral experience in cell signaling, cancer biology, and translational research for development of novel targeted therapies. He is the recipient of a National Research Service Award from the National Institutes of Health.
Currently he is the director of the Cancer Risk program (CaRE) at the Dubin Breast Center at Mount Sinai and has expertise in management of patients at high risk for breast cancer and other malignancies. This program incorporates individual risk stratification and management through prophylactic surgery, risk reducing therapies, and specialized screening protocols. Dr Schmidt is the co-Principal Investigator of the Breast Cancer Biospecimen Repository and has led the design and development of this tissue collection in conjunction with an accompanying comprehensive clinical information system as a tool for breast cancer research.
As a member of the Tisch Cancer Institute, he is also involved in multiple clinical and translational studies through the Dubin Breast Center aimed at improving diagnosis, prognostication, and outcomes for patients diagnosed with breast cancer. Dr Schmidt’s research interests are focused on implementation of truly personalized medicine in breast cancer. Ongoing studies include chemoprevention, development of new blood and tissue biomarkers, utility of neoadjuvant protocols and patient derived tumor models to understand mechanisms of therapeutic resistance.
James Urbanic, MD, is a board-certified radiation oncologist and the medical director of Radiation Oncology Services in Encinitas. He specializes in a variety of radiotherapy and radiosurgical techniques, including intensity-modulated radiation therapy, image guided radiation therapy and stereotactic radiosurgery and stereotactic body radiation therapy.
Dr. Urbanic’s research is focused on breast and lung cancer and cancer symptom management. He has developed and led physician education courses in radiosurgery and stereotactic body radiation therapy techniques. He is involved with national committees for developing clinical trials aimed at improving outcomes for patients with lung cancer. As a faculty member in the School of Medicine’s Department of Radiation Medicine, Dr. Urbanic also enjoys teaching resident physicians and medical students.
Dr. Urbanic previously led the lung cancer, breast cancer and body radiosurgery programs at Wake Forest University Baptist Medical Center. He also completed his residency training at Wake Forest University. Prior to earning his medical degree from the Medical University of South Carolina, he worked on ships all over the world as an engineer and graduate of the U.S. Merchant Marine Academy.
Dr. Urbanic is a member of the American Medical Association, the American Society for Radiation Oncology and the American Society of Clinical Oncology.
Andrew Young, MD, Radiation Oncologist, earned his medical degree from Drexel University College of Medicine and completed a radiation oncology residency at Hahnemann University Hospital (part of the Drexel School of Medicine) in Philadelphia. Dr. Young was a Clinical Instructor on faculty at Dartmouth for several years, and most recently was Medical Director of Radiation Oncology at Southwest Vermont Regional Cancer Center.
“I enjoy the friendly community and natural beauty that Alpena has to offer,” said Dr. Young. “The community and the hospital have a great attitude and appreciation for the people that work in the Alpena Cancer Center. You can see every day how the Cancer Center staff work together to put the patient first. They have a collective spirit of cooperation and it makes me feel good to be a part of the team.”
In addition to the community and hospital, Dr. Young is thrilled to be part of the University of Michigan facility. “The University of Michigan Radiation Oncology is a pillar of quality cancer care and research and working with, my chairman, Dr. Ted Lawrence, an ASTRO Gold Medal Recipient and leader in our field, is an honor,” adds Dr. Young.
About VoyagerMed
VoyagerMed is a medical tourism marketplace for traveling and international patients seeking high-quality medical care in the United States. We connect patients to a curated network of top medical specialists from leading institutions in the U.S. Through VoyagerMed, patients can connect directly with specialists for virtual consultations, second opinions and treatment. The company is based in New York City. For more information visit voyagermed.com, call 212-470-4559 or email info@voyagermed.com.
